DNA Methyltransferases Expression in Triple-negative Breast Cancer Predicts Sensitivity to Decitabine

Liewei Wang

Mayo Clinic

Dr. Wang is a Professor in the Department of Molecular Pharmacology and Experimental Therapeutics at Mayo Clinic Rochester, USA. She received her MD from Fudan University medical school in China, followed by PhD. in pharmacology from Mayo College of Medicine. Her program has been focused on using multiple omics to identify and understand biomarkers associated with various anti-cancer treatments. She has developed both cell line models and breast and prostate PDX models to study resistance mechanisms of anticancer therapies.


Introduction Triple-negative breast cancer (TNBC) is a heterogeneous disease with poor prognosis and lacking targeted therapies especially in patients with chemotherapy resistant disease. Since DNA methylation-induced... [ view full abstract ]


  1. Liewei Wang (Mayo Clinic)
  2. Jia Yu (Mayo Clinic)

Topic Areas

Drug target discovery and integration with individualized therapy, integration of diagnosi , Personalized therapies (cancer, immunology, infectious diseases, clinical case studies, et


PL1c » Plenary Speeches (17:00 - Monday, 25th June, Amphitheater)

Presentation Files

The presenter has not uploaded any presentation files.